A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this clinical trial is to learn if the new administration regimen of VCN-01, given together with the standard chemotherapy drugs gemcitabine and nab-paclitaxel (GnP), is safe and well tolerated. The behaviour of VCN-01 in the organism will be assessed, together with the possible benefits of this administration regimen. This study includes adults with newly diagnosed pancreatic ductal adenocarcinoma (PDAC) that has spread to other parts of the body (stage IV) and who have not received prior treatment for pancreatic cancer. Participants will receive three planned doses of VCN-01, given once every 56 days. Each dose of VCN-01 is followed one week later by two cycles of standard chemotherapy with gemcitabine and nab-paclitaxel. Participants will be monitored throughout the study for safety and side effects.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Nowo rozpoznany rak trzustki (adenokarcynoma) który rozszerzył się na inne części ciała (stadium IV)
- •Brak wcześniejszego leczenia raka trzustki
- •Możliwość otrzymania pierwszej dawki leku w ciągu 6 tygodni od rozpoznania
- •Co najmniej jeden guz widoczny na zdjęciach diagnostycznych
- •Dobry stan ogólny (stan sprawności 0-1)
- •Prawidłowe wyniki badań krwi i funkcji narządów (wątroba, nerki)
- •Prawidłowa funkcja serca (frakcja wyrzutowa lewej komory ≥50%)
✗ Disqualifies
- •Wcześniejsze leczenie raka trzustki (chemioterapia, radioterapia lub inne badane leki)
- •Niezdolność lub niechęć do uczestnictwa w badaniu z powodów geograficznych, psychicznych lub społecznych
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 27, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Hospital 12 de Octubre
Madrid, Spain
Trial contact
Manel Cascalló CEO, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/28/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.